Century Therapeutics, Inc. (IPSC)

USD 1.05

(-10.68%)

Market Cap (In USD)

88.85 Million

Revenue (In USD)

2.23 Million

Net Income (In USD)

-136.67 Million

Avg. Volume

349.09 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.03-5.51
PE
-
EPS
-
Beta Value
1.42
ISIN
US15673T1007
CUSIP
15673T100
CIK
1850119
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Brent Pfeiffenberger M.B.A., Pharm.D.
Employee Count
-
Website
https://www.centurytx.com
Ipo Date
2021-06-18
Details
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.